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Abstract
Background Anastomotic leak after rectal surgery is reported in 9% (range 3–28%) of patients. The aim of our study was 
to evaluate the effectiveness of endosponge therapy for anastomotic. Endpoints were the rate of restored continuity and the 
functional bowel outcome after anastomotic leakage.
Methods This was a multicenter retrospective observational cohort study. All patients with symptomatic anastomotic leakage 
after rectal surgery who had endosponge therapy between January 2012 and August 2017 were included. Functional bowel 
outcome was measured using the low anterior resection syndrome (LARS) score system.
Results Twenty patients were included. Eighteen patients had low anterior resection (90%) for rectal cancer. A diverting 
ileostomy was performed at primary surgical intervention in 14 patients (70%). Fourteen patients (70%) were treated with 
neoadjuvant (chemo-)radiotherapy. The median time between primary surgical intervention and first endosponge placement 
was 21 (5–537) days. The median number of endosponge changes was 9 (2–28). The success rate of the endosponge treat-
ment was 88% and the restored gastrointestinal continuity rate was 73%. A chronic sinus occurred in three patients (15%). 
All patients developed LARS, of which 77% reported major LARS.
Conclusions Endosponge therapy is an effective treatment for the closure of presacral cavities with high success rate and lead-
ing to restored gastrointestinal continuity in 73%. However, despite endosponge therapy many patients develop major LARS.
Keywords Rectal neoplasms · Anastomotic leak · Endosponge · Patient reported outcome measures · LARS score
Introduction
Anastomotic leakage (AL) after rectal surgery is reported 
in 9% (range 3–28%) of the patients and is associated with 
forming of presacral abscesses, emergency surgery, morbid-
ity, permanent colostomy, prolonged hospital stay and even 
mortality [1]. Several risk factors have been associated with 
A; level of the anastomosis, neoadjuvant (chemo)-radiother-
apy (CRT), male gender, tumor size and other comorbidi-
ties [2–4]. A recent study reported 30-day postoperative AL 
rate of 13.4% in patients with rectal cancer surgery, which 
increased during follow-up to 20% [5].
A significant proportion (36%) of patients with AL 
develop a chronic sinus, 50% of which may heal spontane-
ously over time [5, 6]. Conventional treatment consists of 
antibiotics, radiological therapy (transanal or transgluteal 
drainage) or surgical therapy (diverting loop ileostomy, 
endoluminal drainage or dismantling of the anastomosis).
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Endosponge therapy is a relatively novel minimally inva-
sive endoluminal vacuum therapy for presacral abscesses 
that aims to clean the presacral cavity that subsequently 
collapses [7–10]. Therefore, it may prevent the develop-
ment of a chronic sinus and may improve the anastomotic 
healing rate. A review by Strangio et  al. reported high 
success (94%) of endosponge therapy for the treatment of 
presacral abscesses [11]. Gardenbroek et al. reported high 
effectiveness of vacuum-assisted early transanal closure of 
AL in patients with inflammatory bowel disease (IBD) who 
had ileal pouch–anal anastomosis (IPAA) [12]. Borstlap 
et al. recently demonstrated restored gastrointestinal conti-
nuity in 67% of the patients who had vacuum-assisted early 
transanal closure after AL, especially when the endosponge 
therapy was started within 3 weeks of primary surgical 
intervention [13]. The aim of our study was to evaluate the 
effectiveness of endosponge therapy. Endpoints were the rate 
of restored continuity and the functional bowel outcome in 
patients with anastomotic leakage after rectal surgery.
Materials and methods
Study design and patient selection
This retrospective cohort study was performed in two Dutch 
high-volume colorectal cancer centers: Isala hospital and 
IJsselland hospital. All eligible patients with symptomatic 
AL after rectal surgery treated with endosponge therapy 
between January 2012 and August 2017 were included. 
Patients with postoperative signs of AL and AL confirmed 
by computed tomography (CT) scan were considered eligi-
ble. Patients with colonic cancer, patients who underwent 
Hartmann’s procedure as primary surgical procedure and 
patients who underwent transanal endoscopic microsurgery 
(TEM) were excluded. The study was approved by the medi-
cal ethics committee of Isala hospital (reference number: 
171215).
All patients were discussed in a preoperative multidisci-
plinary team meeting and had an open or laparoscopic total 
mesorectal excision (TME) or IPAA. In case of surgery 
for rectal cancer, neoadjuvant short-course radiotherapy 
(5 × 5 Gy.) or long-course chemo-radiotherapy was given 
depending on the stage of disease. The presacral abscess 
was evaluated during every endosponge exchange. The 
abscess was considered closed if the cavity was covered 
with granulation tissue and the size of the cavity was too 
small for another endosponge placement. At that moment, 
the endosponge therapy stopped.
Endosponge procedure
The endosponge therapy was performed with or without 
conscious sedation depending on the patient’s preference. 
Depending on the size of the cavity 1–3 polyurethane 
endosponges (Endo-SPONGE®, B. Braun Medical B.V., 
Melsungen, Germany) were placed in the deepest point of 
the presacral cavity through a plastic overtube under endo-
scopic guidance. If necessary, the endosponge was tapered 
to achieve collapse of the cavity. The endosponge was con-
nected to a vacuum suction device that created a constant 
negative pressure of 150 mmHg. The endosponges were 
changed twice a week to prevent the granulation tissue 
from growing into the endosponge. In most patients, the 
first endosponge was placed by the surgeon and gastro-
enterologist together. If needed, the anastomotic defect 
was dilated with an endoscopic balloon to facilitate drain-
age and the placement of the endosponge which if nec-
essary was done under radiologic assistance. The next 
endosponge changes were performed by the gastroenter-
ologist alone. Depending on surgeon preference, transanal 
closure of the defect was performed after a short period 
of endosponge therapy (vacuum-assisted early transanal 
closure) to achieve shorter endosponge therapy duration. 
A detailed description of this procedure can be found in 
the paper of Borstlap et al. [13].
Outcomes
Primary outcome was the restored gastrointestinal continuity 
rate at the end of the follow-up.
Secondary outcomes were the success rate of the 
endosponge therapy, presence of a chronic sinus and 
the functional bowel outcome after AL. Success of the 
endosponge treatment was defined as a cavity reduced in 
size and covered with granulation tissue that was too small 
to allow placement of a new endosponge at the end of the 
endosponge therapy. A chronic sinus was defined as a proven 
presacral abscess that was still present 1 year after primary 
surgical intervention.
Functional bowel outcome
Functional bowel outcome was assessed postoperatively 
using the validated quality of life questionnaire (low ante-
rior resection syndrome score (LARS score)) [14, 15]. 
The results of the LARS score were categorized into three 
groups: (1) no LARS (0–20 points), (2) minor LARS (21–30 
points) or (3) major LARS (31–42 points).
A control group was created using the institutional colo-
rectal cancer database, consisting of patients with rectal 
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cancer without AL. These patients were matched with the 
endosponge group for CRT.
Statistical analysis
All analyses were performed using Statistical Package of 
Social Sciences version 22 (SPSS). A p value < 0.05 was 
considered significant. Normality was tested using Kol-
mogorov–Smirnov test. Normally distributed variables were 
described as mean with standard deviation (StD) and non-
parametrical distributed variables were described as median 
with range. Categorical data were tested using Chi-square 
test or Fisher’s exact test. Normally distributed continuous 
data were tested using Student’s T test. Non-parametrical 
continuous data were tested using Mann–Whitney U test. 
Additionally, the non-parametrical continuous data were 
divided into two groups based on the median and tested 
with Chi-square or Fisher’s exact test. Survival analysis 
was performed to estimate the probability for stoma rever-
sal and success rate of the endosponge after resection using 
Kaplan–Meier analysis. Start of follow-up was primary 
resection and end of follow-up was date of interest; stoma 
reversal date, last endosponge exchange date, date of death 
or end of follow-up. End of follow-up for patients without 
stoma reversal or not censored was last hospital visit.
For subgroup analysis, patients were divided into early 
and late endosponge groups based on the median number 
of days between primary surgical intervention and start of 
the endosponge therapy. Patients who started endosponge 
therapy before the median cutoff point were allocated 
to the early endosponge group and patients who started 
endosponge therapy on or after the cutoff point were allo-
cated to the late endosponge group. The difference in stoma 
reversal between early and late endosponge groups was cal-
culated using the log rank test.
A multivariate linear regression analysis was performed 
to determine whether occurrence of AL influences the LARS 
scores taking into account other potential confounders or 
patient characteristics at baseline.
Results
Baseline characteristics
A total of 20 patients were eligible for inclusion in our study. 
Baseline characteristics are presented in Table 1. Fourteen 
of 20 (70%) patients were diverted during primary surgery. 
Three of the six patients who were not initially diverted 
at primary surgical intervention were diverted at the time 
AL was detected, two patients received endosponge ther-
apy without diverting ileostomy and the other patient had 
Hartmann’s procedure followed by endosponge therapy of 
the presacral abscess. Reintervention before the start of the 
endosponge therapy was performed in 8 of 20 patients: sur-
gical drain placement (n = 4), diverting ileostomy (n = 3) 
and dismantling of the anastomosis with Hartmann’s pro-
cedure (n = 1). In 3 of the 20 enrolled patients, the anasto-
motic defect was transanally closed after a median of 2 [2, 
3] endosponge changes.
The median time between primary surgical intervention 
and anastomotic leak detection, median time between pri-
mary surgical intervention and first endosponge placement, 
median number of endosponge changes and median dura-
tion of the endosponge therapy are presented in Table 2. No 
endosponge-related adverse events were reported.
Table 1  Baseline characteristics
a Count (%), bMedian [range], cFischer’s exact test, dMann–Whitney U test, eStudent’s t test
Total patients Early endosponge Late endosponge p value
n 20 10 10
Malea 14 (70) 5 (50) 9 (90) 0.14c
Age (years)b 64 ± 10 64 ± 11 64 ± 10 0.95e
Distance (cm) from anal  vergeb 8.5 [5–12] 8 [6–12] 9 [5–10] 0.27d
Etiologya 0.47c
 Rectal cancer 18 (90) 8 (80) 10 (100)
 Inflammatory bowel disease 2 (10) 2 (20) –
Type of  procedurea 0.47c
 Total mesorectal excision 18 (90) 8 (80) 10 (100)
 Ileal pouch–anal anastomosis 2 (10) 2 (20) –
Laparoscopic  procedurea 16 (80) 9 (90) 7 (70) 0.58c
Neoadjuvant chemo-radiotherapya 14 (70) 5 (50) 9 (90) 0.14c
 Short-course neoadjuvant therapy 11 (55) 4 (40) 7 (70)
 Long-course neoadjuvant therapy 3 (15) 1 (10) 2 (20)
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Outcome of endosponge therapy
Endosponge treatment was successful in 17 of 20 patients 
(85%). In 14 of the 20 patients (70%), continuity was 
restored. Six patients received a definitive stoma because 
of a chronic sinus (n = 3), proctectomy (n = 1), local recur-
rence (n = 1) and one patient died because of tumor pro-
gression. A chronic sinus has developed in three patients 
(15%). The median time from primary resection to stoma 
reversal was 10 [3–15] months (Table 2). The overall cumu-
lative probability of endosponge therapy success was 88% 
(95% CI = 57–97%) and the overall cumulative probability 
of stoma removal was 73% (95% CI = 44–87%). Individual 
follow-up characteristics after primary resection are pre-
sented in Fig. 1.
Outcome of early versus late endosponge group
Ten patients were classified as being in an early endosponge 
group and 10 patients in a late endosponge group based on 
the study median of 21 days from primary surgery until first 
endosponge placement. Reasons for the delay of endosponge 
placement in the late endosponge group were: the presacral 
abscess became clinical relevant only after 3 weeks (n = 5), 
re-laparotomy with surgical drainage (n = 2), end colostomy 
(n = 1), diverting ileostomy (n = 1) and antibiotic therapy 
prior to endosponge therapy (n = 1). An overview of the 
results of the early and late endosponge therapy is presented 
in Table 2.
In the early group, the endosponge therapy was suc-
cessful in 8/10 patients and anastomotic healing occurred 
in 7/10  patients. Two patients had a permanent colostomy 
because of a chronic sinus, unresolved by endosponge. The 
other patient without restored gastrointestinal continuity 
died 6 months after endosponge therapy because of tumor 
progression. The median time until stoma reversal was 7 
months. In the late endosponge group, the endosponge 
therapy was successful in 9/10 patients and anastomotic 
healing occurred in 7/10 patients. Three patients did not 
have intestinal continuity restored because of: chronic sinus 
Table 2  Clinical outcome of 
endosponge treatment
a Count (%), bMedian [range], cMann–Whitney U
Total group Early endosponge Late endosponge p value
Days until anastomotic leak  detectionb 12 [3–67] 10 [3–19] 21 [4–67] 0.10c
Days until first  endospongeb 21 [5–537] 11 [5–20] 30 [21–537] < 0.001c
Endosponge  changesb 9 [2–28] 6 [2–28] 14 [2–26] 0.45c
Duration endosponge therapy (days)b 25 [3–115] 20 [3–115] 25 [5–80] 0.79c
Median follow-up (months)b 10 [3–84] 8 [3–25] 12 [6–84] 0.08c
Success endosponge  therapya 17 (85) 8 (80) 9 (90) –
Restored  continuitya 14 (70) 7 (70) 7 (70) –
Time until stoma  reversalb 10 [3–15] 7 [3–11] 10 [6–15] 0.15c
Chronic  sinusa 3 (15) 2 (20) 1 (10) –
Fig. 1  Individual follow-up characteristics after resection. Fourteen patients (70%) were reversed successfully. *No primary diverting stoma. 
Filled triangle: end of endosponge and determining success rate of endosponge. †Deceased
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(n = 1), local recurrence (n = 1) and proctectomy (n = 1). The 
patient with a permanent colostomy due to a chronic sinus 
was treated in the beginning with conventional therapy and 
has eventually started endosponge therapy 537 days after 
primary surgical resection without success. The median time 
until stoma reversal in the late endosponge group was 10 
months.
The overall cumulative probability of stoma removal 
for patients in the early endosponge group was 77% (95% 
CI = 22–93%) compared with 70% (95% CI = 23–88%) for 
patients in the late endosponge group. This difference in 
absolute risks was not statistically significant (p = 0.31). 
Also, no statistically significant difference in the success rate 
of endosponge therapy and the presence of a chronic sinus 
was found between the early and late endosponge groups.
Quality of life
Fourteen patients who had endosponge treatment received 
the questionnaire. Six patients were not invited to fill in the 
questionnaire because of a permanent colostomy. Thirteen 
patients (93%) responded to the questionnaire. Thirty-two 
patients in the control group (without AL) received the ques-
tionnaire. Twenty-one (66%) of them responded to the ques-
tionnaire. Baseline characteristics between the endosponge 
group and the control group are presented in Table 3.
The median LARS score in the endosponge group was 
37 (23–42) points and 30 (4–41) points in the control group 
(p = 0.009). The median time between stoma reversal and 
date of the quality of life questionnaire was 2.6 (0.8–3.5) 
years in the endosponge group and 2.3 (1.8–2.8) years in the 
control group (p = 0.47). No significant difference between 
these two groups in age, response to questionnaire time, dis-
tance to anal verge, CRT and laparoscopy procedure was 
found. In the endosponge group, three patients (23%) had 
minor LARS and ten patients (77%) had major LARS. In the 
control group, five patients (24%) had no LARS, six patients 
(29%) had minor LARS and ten patients (48%) had major 
LARS. In the multivariate analysis, the LARS score was sig-
nificantly associated with endosponge therapy (β = − 7.595, 
p = 0.02) (Table 3). No significant difference in LARS scores 
was found between the early and late endosponge groups 
(p = 0.72).
Discussion
We reported a large series of 20 patients who were treated 
with endosponge therapy after AL. This study is, to the best 
of our knowledge, the first study that describes the long-
term functional bowel outcome after endosponge therapy 
in patients with AL compared with a control group con-
sisting of patients without AL after TME. The majority of 
our patients (90%) were treated for rectal cancer and 70% 
of the patients received neoadjuvant (chemo-)radiotherapy. 
There was a high success rate (88%) of endosponge therapy, 
restored bowel continuity rate of 73% and major LARS in 
77% of the patients after endosponge therapy.
These findings are in line with previous studies that 
reported on the outcome of endosponge therapy. Mussetto 
et al. reported successful endosponge therapy with restored 
gastrointestinal continuity in 10 of the 11 patients (91%) 
after anastomotic leakage [16]. Strangio et al. described a 
completely healed cavity after endosponge therapy in 94% 
of the cases and anastomotic healing in 56–92% of the cases 
[11]. The majority (90%) of these patients were treated 
for rectal cancer and patients with generalized peritonitis 
were excluded. Borstlap et al. demonstrated an anastomotic 
healing rate of 67% in patients with AL who had vacuum-
assisted early transanal closure [13]. However, 93% of the 
Table 3  Baseline characteristics 
of patients who developed 
LARS
LARS low anterior resection syndrome
a Count (%), bMedian [range], cFischer’s exact test, dMann–Whitney U test, eStudent’s t test
Endosponge after anas-
tomotic leakage
No anastomotic leakage p value
LARS  scoreb 37 [23–42] 30 [4–41] 0.009d
 Major  LARSa 10 (77) 10 (48)
 Minor  LARSa 3 (23) 6 (29)
 No  LARSa – 5 (24)
Age (years)b 67 ± 7 64 ± 8 0.43e
Response time questionnaire (years)b 3.1 [1.5–4.5] 2.6 [2.3–2.8] 0.26d
Time from stoma reversal to question-
naire date (years)b
2.6 [0.8–3.5] 2.3 [1.8–2.8] 0.46d
Distance tumor to anal verge (cm)b 8.5 [5–12] 10 [5–15] 0.07d
Neoadjuvant chemo-radiotherapya 8 (62) 16 (76) 0.36c
Laparoscopic  procedurea 10 (77) 19 (91) 0.35c
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patients had persistent AL 2 weeks after transanal closure, 
requiring conservative monthly endoscopic follow-up (43%), 
redo endosponge therapy (32%), redo transanal surgical 
closure (18%), percutaneous drainage (4%), or end colos-
tomy (4%). Furthermore, they reported that early start of 
endosponge therapy (before 3 weeks) resulted in higher 
stoma reversal rate and lower proportion of a chronic sinus. 
Therefore, early treatment of the presacral abscess might 
be advocated to improve anastomotic healing rates and 
reduce the development of a chronic sinus. Our study dem-
onstrated a similar success rate of the endosponge therapy, 
similar anastomotic healing rates and a lower proportion of 
a chronic sinus compared to Borstlap et al. [13]. We found 
no significant difference in our study between the early and 
late endosponge groups for these parameters.
A chronic sinus occurred in 15% of the patients in our 
study. Previous studies reported a persistent sinus rate at 
1 year of 48% after AL without endosponge therapy [5, 6]. 
The proportion of chronic sinus found in our study is low 
compared to these studies, suggesting that endosponge is a 
good therapy to prevent the development of chronic sinus. 
However, endosponge was not used in these two earlier stud-
ies. Furthermore, a study reported a late abscess in 25% 
of the patients after successful endosponge. A prolonged 
interval between primary surgery and AL detection was the 
only predictive factor in this study [17]. Until now, no late 
abscesses were seen in our study.
AL and chronic sinus are associated with impaired func-
tional bowel outcome. Improvements of the functional bowel 
outcome can be expected especially in the first year after 
surgery. In the following years, the functional outcome 
will remain stable [18]. We assessed the functional out-
come using the LARS score questionnaire after a median 
of more than 2 years after stoma reversal. Patients with 
AL who had endosponge therapy had significantly higher 
LARS scores than patients without AL in the control group. 
We used patients without AL as a control group, because 
most patients who presented with AL that did not have 
endosponge therapy had their anastomosis taken down or 
resected and received an end colostomy.
All patients in our study had LARS (77% had major 
LARS and 23% minor LARS) after endosponge therapy 
compared to 76% in the control group. Borstlap et al. also 
reported high LARS scores after combined surgical and 
endoscopic treatment for AL (81% had major LARS and 
13% minor LARS) [13]. A systematic review of patients 
without AL following rectal cancer surgery reported major 
LARS in 38–62%, minor LARS in 22–28% and no LARS 
in 10–38% [19].
Our study and the results from the previous literature 
mentioned above demonstrate that patients with AL who 
had endosponge therapy have a higher risk of developing 
(severe) LARS compared with patients without AL. The 
main causes of LARS are probably the AL and fibrosis 
in the abscess cavity during endosponge therapy causing 
reduced neorectal compliance. Another explanation of our 
high LARS scores after endosponge therapy could be that 
the endosponge group has a lower anastomosis than the 
patients in the control group, although this was not a sta-
tistically significant difference. No significant difference in 
functional bowel outcome was found between the early and 
late endosponge groups.
Limitations of this study are the small number of included 
patients and the long period over which patients were 
entered into our database, even though we have reported the 
fifth largest series worldwide. There might have been selec-
tion bias because of the retrospective design. Patients diag-
nosed with AL who were offered other therapies (i.e., dis-
mantling of the anastomosis with creation of an end or loop 
colostomy) or transanal tube drainage were not included in 
our analysis. Patients with abdominal sepsis or generalized 
peritonitis were selected for dismantling of the anastomosis 
rather than endosponge therapy. Furthermore, no baseline 
LARS questionnaires were used.
Endosponge therapy resulted in a high rate of restored 
gastrointestinal continuity. Despite this positive outcome, 
a substantial number of patients had major LARS after an 
AL and endosponge therapy. This factor together with the 
duration of the therapy with several endosponge changes, 
frequent hospital visits, psychological factors and the occur-
rence of late abscess recurrence after successful endosponge 
therapy needs to be considered before the start of the 
endosponge therapy and could be of importance for the 
informed consent procedure. Future studies should evalu-
ate which patients benefit from endosponge therapy over 
conventional treatment.
Conclusions
Our results show that endosponge therapy is an effective 
treatment for the closure of presacral cavities after rectal sur-
gery with high success rate (88%) leading to restored gastro-
intestinal continuity in 73% of patients. A significant propor-
tion of patients developed major LARS despite endosponge 
treatment. This should be taken into consideration when 
contemplating salvaging an anastomosis with endosponge.
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